Synergism between circulating tumor necrosis factor receptor 2 and HbA 1c in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria

Diabetes Care

Volumn 37, Issue 9, 2014, Pages 2601-2608

  Skupien, Jan ^a,b,c   Warram, James H ^a,b   Niewczas, Monika A ^a,b   Gohda, Tomohito ^a,b,d   Malecki, Maciej ^c   Mychaleckyj, Josyf C ^e   Galecki, Andrzej T ^f   Krolewski, Andrzej S ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MICROALBUMINURIA; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PROTEINURIA; RISK FACTOR; SCHOOL CHILD; BLOOD; COMPLICATION; DRUG POTENTIATION; FOLLOW UP; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MALE; PATHOPHYSIOLOGY; PROGNOSIS; TIME;

ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; PROGNOSIS; PROTEINURIA; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TIME FACTORS;

EID: 84906656078     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1983     Document Type: Article

References (18)

1. Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23:516-524
2. Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012;23:507-515
3. Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22:545-553
4. Skupien J, Warram JH, Smiles AM, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 2012;82: 589-597
5. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000;1:465-480
6. Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Stat 2004; 58:16-24
7. Rubin DB. Inference and missing data. Biometrika 1976;63:581-592
8. Schluchter MD, Greene T, Beck GJ. Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease. Stat Med 2001;20:989-1007
9. Levey AS, Stevens LA, Schmid CH, et al.; CKDEPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612
10. NiewczasMA, Ficociello LH, Johnson AC, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009;4:62-70
11. Wu MC, Hunsberger S, Zucker D. Testing for differences in changes in the presence of censoring: parametric and non-parametric methods. Stat Med 1994;13:635-646
12. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387
13. Kremers WK. Concordance for Survival Time Data: Fixed and Time-Dependent Covariates and Possible Ties in Predictor and Time. Rochester, MN, Mayo Clinic, 2007 (Tech. Rep. Ser., no. 80)
14. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group. Baseline markers of inflammation are associated with progression tomacroalbuminuria in type 1 diabetic subjects. Diabetes Care 2013; 36:2317-2323
15. Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression tomacroalbuminuria. Diabetes Care 2014;37:226-234
16. Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS. Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol. 5 June 2014 [Epub ahead of print]
17. de Boer IH, Sun W, Cleary PA, et al.; DCCT/ EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-2376
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986